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Background There is no specific serum-based biomarker for the diagnosis or prognosis of relapsing-
remitting multiple sclerosis (RRMS).
Objective We investigated whether levels of IgM antibodies to Glc(α1,4)Glc(α) (GAGA4) or to a
panel of four glucose-based glycans could differentiate MS from other neurological diseases (OND)
or predict risk of early relapse following first presentation (FP) of RRMS.
Methods Retrospective analysis of 440 sera samples of three cohorts: A) FP-RRMS (n = 44), OND
(n = 44); B) FP-RRMS (n = 167), OND (n = 85); and C) FP (n = 100). Anti-GAGA4 IgM levels were
measured by enzyme immunoassay in cohort-A and cohort-B. Cohort-C IgM antibodies to glucose-
based glycan panel were measured by immunofluorescence.
Results FP-RRMS had higher levels of anti-GAGA4 IgM than OND patients (cohort-A, P = 0.01;
cohort-B, P = 0.0001). Sensitivity and specificity were 27% and 97% for cohort-A; and 26% and
90% for cohort-B, respectively. In cohort-C, 58 patients experienced early relapse (<24 months), 31
had late relapse (≥24 months), and 11 did not experience second attack during follow-up. Kaplan–
Meier curves demonstrated decrease in time to next relapse for patients positive for the antibody
panel (P = 0.02, log rank).
Conclusions Serum anti-GAGA4 IgM discerns FP-RRMS patients from OND patients. Higher levels of
serum anti-α-glucose IgM in FP patients predict imminent early relapse. Multiple Sclerosis 2009; 15:
422–430. http://msj.sagepub.com
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Introduction
Multiple sclerosis (MS) is an inflammatory demye-
linating disease of the central nervous system
(CNS), although the exact etiology and pathogene-
sis have not yet been deciphered. The finding of
IgG antibody formation specifically in the cerebro-
spinal fluid (CSF), but not in a corresponding serum
(i.e. oligoclonal banding), has long been a useful
test for diagnosis and differential diagnosis of MS
[1], though no known antigenic specificity has
ever been universally defined. The search has been
ongoing for useful serum-derived biomarkers,
including antibodies. Serum IgM antibodies to an
N-glucosylated peptide were specifically increased
in relapsing-remitting multiple sclerosis (RRMS)
patients [2,3]. High antibody titers to two myelin
peptides, myelin oligodendrocyte glycoprotein and
myelin basic protein were reported by some [4], but
not others [5], to predict early relapse in patients
after their first presentation (FP) of MS.
We previously demonstrated elevated levels of
IgM antibodies to Glc(α1,4)Glc(α) (GAGA4) in
RRMS patients in comparison to patients with
other neurological diseases (OND) [6]. We were,
therefore, interested in knowing when in the course
of disease higher antibody titers to GAGA4 or
a panel of glucose-based glycans first occurs or
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ity by focusing on patients studied after their FP.
Materials and methods
Serum Samples
A retrospective study of frozen (−70°C) and
rethawed serum samples collected from patients
at the time of diagnostic work-up for their FP were
later diagnosed as RRMS. The control group
included sera samples taken from patients with
OND that were stored around the same time from
routine samples sent to the respective CSF diagnos-
tic laboratories. Demographic and clinical data were
obtained from hospital records. Inclusion criteria
for MS samples were as follows: patient age
(18–60 years) at time of sampling, follow-up for at
least 4 years from blood sampling, and diagnosis of
RRMS according to Poser criteria [7], or as OND.
Samples which meet the above criteria were identi-
fied from one of two serum repositories located
at the Ottawa Hospital-General Campus, Ottawa,
Canada (Mark S. Freedman) between the years
1993 and 2001 or the Cliniques Universitaires
Saint-Luc in Brussels, Belgium (Christian Sindic)
between the years 1998 and 2002. Samples were
collected under a broad consent for scientific
research allowing for multiple studies and approved
by local ethics boards. Relapse was defined as any
new neurological event accompanied by symptoms
or signs, or significant worsening of previous symp-
toms or signs in the absence of fever that lasted at
least 48 hours. All samples were encoded at respec-
tive institutions before being sent to Glycominds
Ltd. laboratories for antibody analysis—decoding
occurred only after all the analyses were completed.
Three distinct cohorts were analyzed: cohort-A
included 88 samples (44 FP n = 44, OND n = 44),
OND patients were matched to the MS patients
according to age and gender; cohort-B included
252 samples (FP n = 167, OND n = 85); and cohort-
C included 100 FP patients. All samples were
assayed in a ‘blinded’ fashion.
Total IgM measurement
Total IgM level was measured as previously
described [6] and reported in relative fluorescence
units (RFU) (cohort-A). For cohort-B and cohort-C,
total IgM levels were measured using a commercial
enzyme-linked immunosorbent assay (ELISA) kit
(Bethyl laboratories, Montgomery, TX) according
to manufacturer instructions and reported in milli-
gram per milliliter.
Enzyme-linked immunoassay of anti-GAGA4 IgM
In cohort-A and cohort-B, levels of anti-GAGA4
IgM were determined in IgG depleted samples by
enzyme-linked immunoassay (EIA) and normalized
according to the levels of total IgM as previously
reported [6]. IgG depletion was performed using a
commercial mini Rapi-Sep® units (PanBio, Balti-
more, MD) according to manufacturer’s instruc-
tions. p-nitrophenyl derivative of GAGA4 were
covalently attached to the surface of a 96-well
microtiter plate via a linker as previously described
[8]. Serum samples were diluted 1:1200 in a sample
diluent (Cat. No. G300023, Glycominds, Lod,
Israel), dispensed into the wells in duplicates, and
incubated for 120 min in 5°C, then washed with
wash buffer (Cat. No. G300022, Glycominds Ltd).
Bound antibodies were labeled with horseradish
peroxidase-conjugated goat anti-human IgM type-
specific antibody (1:2000), washed, and 3, 3′,5 ,5 ′-
tetramethylbenzidine was added for detection. After
30 min, the enzymatic reaction was stopped with
1% sulfuric acid solution and optical density (OD)
of the wells was read at 450 nm with a Victor 1420
plate reader (Wallac, Turku, Finland). In cohort-A,
anti-GAGA4 OD levels were normalized by dividing
them by the square root of total IgM levels (RFU)
multiplied by 106. Cutoff value was set as mean
[OD/(total IgM × 106)0.5] level of OND group + 2
standard deviations (SD).
In cohort-B, in addition to the tested samples,
each plate included positive- and negative-control
sera samples from MS patients and a calibrator sam-
ple considered as 50 units. Anti-GAGA4 EIA units
(EU) values were calculated for each sample by
dividing the sample ODs by the calibrator OD mul-
tiplied by 50. Anti-GAGA4 EU were normalized for
total IgM in serum samples, by dividing by the
square root of total IgM (mg/mL)0.5 corrected to
gender by adding 0.17 (mg/mL)0.5 for male samples.
Cutoff value for determination of anti-GAGA4 pos-
itivity was 42 EU/(mg/mL)0.5. This cutoff was based
on receiver operator characteristic curve analysis for
achieving 90% specificity for RRMS. The coefficient
of variation (CV) of anti-GAGA4 ELISA level was 11%
between wells in the same plate (intra-plate), and
15% for different assays (inter-plate). Inter-plate con-
stant variance for calibrator sample was 15%.
Immunofluorescence assay for anti-GAGA2,
-GAGA3, -GAGA4, and -GAGA6 IgM
using glycan array
Glycan array
Levels of anti-GAGA2, -GAGA3, -GAGA4, and
-GAGA6 IgM antibodies in cohort-C samples were
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slides patterned with teflon mask, creating 7 clus-
ters of microwells with 32 wells in each cluster
(Figure 1A). An adhesive silicon superstructure
(Figure 1B) was attached to the slide. This silicon
gasket defined wells for manual application of
multiple serum samples per slide. Each well was
arrayed with glycan antigens and internal controls
(Figure 1C). p-nitrophenyl derivatives of GAGA2,
GAGA3, GAGA4, and GAGA6 (Toronto Research
Chemicals, Toronto, Canada) were covalently
bound by a linker to the glass slide as previously
described [6].
Assay procedures
The slide wells were incubated for 60 min at room
temperature with blocking solution (400 μL/well).
After removal of blocking solution, 300 μL/well of
patients’ sera, diluted 1:40 in aqueous solution of
1% bovine serum albumin in 20 mM Tris–HCl
pH 7.2, 0.9% NaCl, 0.05% Tween-20 was added to
each well. Each slide included five sera samples and
a reference sample for one arbitrary unit. Each sam-
ple was tested five times on different slides. Samples
were incubated for 45 min. Following sera were
removed and slides further washed and processed
in an HS4800 system. Briefly, slides were washed
in TNTT buffer (20 mM Tris–HCl pH 7.2, 2 M NaCl,
0.05% Tween-20, 0.05% Triton X-100) by the
hybridization system. Biotinylated goat anti-
human IgM (1:500) and Alexa-633-labeled strepta-
vidin (1:150; Molecular Probes Inc. Eugene, OR,
USA) were incubated sequentially with washings
in between for 1 h at 32°C in the light-protected
and temperature-controlled environment of the
hybridization system.
Following the washing and drying, slides
were scanned using laser scanner (GenePix 4000B,
Figure 1 Glycan array format: A – Glass slide patterned with Teflon mask creating 7 clusters of microwells, 32 wells in each
cluster. B – An adhesive silicon superstructure attached to the slide defines wells for manual application of multiple serum
samples per slide. C – Antigens and controls lay out in each gasket well.
424 MS Freedman et al.
Multiple Sclerosis 2009; 15: 422–430 http://msj.sagepub.comMolecular Device, Baltimore, MD); slide image was
analyzed using Optiquant™ software and RFU
representing relative binding of anti-glycan IgM to
each antigen and control micro-well were calcu-
lated. The data quality from each well was verified
by ensuring signal levels from human IgM and
anti-human IgM spots above cutoff. If the data
quality from the wells did not meet criteria, samples
were tested again. Levels of anti-GAGA2, -GAGA3,
-GAGA4, and -GAGA6 IgM were calculated for each
sample by dividing the sample RFU by the reference
sample RFU. The CV of anti-α-glucose levels was
8–12% for intra-slides wells and 15–22% for differ-
ent hybridization station running cycles (inter-
slide).
Samples were considered as positive if results
were above cutoff levels for at least one of the four
antibodies. Cutoff values for each antigen were cal-
culated as mean value of the FP population plus 1,
1.5, or 2 SD, and best fit cutoffs (4.0, 4.5, 4.5,
and 4.3 for anti-GAGA2, -GAGA3, -GAGA4, and
-GAGA6 IgM, respectively).
Statistical methods
Numerical variables were compared across groups
by Student’s t-test or by the Mann–Whitney U-test,
depending on whether or not they followed a nor-
mal distribution, and the χ2 test for rates compari-
son between groups or the Fisher exact if any cells
had an expected count of less than 5. Pearson cor-
relations were calculated between numerical vari-
ables. P-values of less than 0.05 were considered to
be statistically significant. Uncertainty of results
was expressed by 95% confidence intervals. For
comparison between FP patients and OND patients,
levels of anti-GAGA4 IgM EU were corrected for
total IgM level by dividing them by the square
root of total human IgM in the sample. Diagnostic
accuracy was calculated by sensitivity, specificity,
positive predictive value (PPV), and negative predic-
tive value (NPV). Predictive values were calculated
based on the prevalence of MS in the present cohort
(0.68). The cumulative risk of the development of
clinically definite MS (CDMS) was calculated for
each group according to the Kaplan–Meier method,
and the differences between the groups were evalu-
ated in a univariate analysis by the log-rank test.
We implemented a two-stage analysis for testing
the ability of GAGA4 to differentiate OND from FP
subjects. In the first stage, a preliminary analysis on
OND and FP groups that were age- and gender-
matched (cohort-A) were performed. Our aim was
to explore the ability of an anti-GAGA4 assay to dif-
ferentiate between OND and FP subjects under con-
ditions that maximize the power of detection of
disease-specific effects. In the second stage, we
tested if the results from the preliminary analysis
could be repeated by a more optimal EIA method
in a different and relatively larger population in
which the FP and OND groups were not matched
for age and gender (cohort-B).
For testing the ability of the marker antibodies to
differentiate FP patients with a high risk vs. a low
risk for early conversion to CDMS (cohort-C), sev-
eral cutoff values were investigated. Although this
analysis involved the application of multiple statis-
tical tests that would normally require the applica-
tion of a correction factor, our study was in fact
exploratory, which beckons multiple analyses in
order to obtain testable hypotheses that would
require confirmation in subsequent studies [9]. We
nevertheless applied a Bonferroni correction factor
to our analysis.
Results
Cohort-A: Anti-GAGA4 IgM in FP-RRMS vs.
OND group
Clinical and demographic characteristics as well as
anti-GAGA4 levels for cohort-A are described in
Table 1. The OND and FP groups were matched for
age and gender. In cohort-A, there were significant
differences between the Brussels and Ottawa groups
regarding gender composition, and a higher num-
ber of samples from Ottawa in the FP group versus
the OND group. However, no significant difference
regarding the levels of total IgM and anti-GAGA4
IgM normalized to total IgM was found between
the 22 samples from Brussels in comparison to the
66 samples from Ottawa. Levels of anti-GAGA4 IgM
normalized to total IgM were significantly higher
(P = 0.01) in samples from FP patients compared to
OND controls. Distribution of normalized anti-
GAGA4 IgM in the FP and OND groups is shown
in Figure 2.
Using the results from the OND patients, we set
a cutoff value for anti-GAGA4 IgM antibodies
of mean OD + 2 SD as 0.53[OD/(Total IgM
RFU × 106)0.5]. Using this cutoff value it was possi-
ble to identify patients who had high levels of anti-
GAGA4, who were later diagnosed as RRMS with a
sensitivity of 27.3% (95% −CI [15–43]) and specific-
ity of 97.7% (95% CI [88–99]), PPV 92.3%, and
NPV 52.3%.
Cohort-A: Identifying FP patients who will have
a second attack within 24 months
Data regarding the time period between blood
extraction and first relapse was available for 41/44
FP patients. Twenty-six out of forty-one FP patients
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sampling. Mean age of these patients was signifi-
cantly lower than those suffering from a second
attack later (mean age 34 versus 42 years,
P = 0.001); however, no association was found
between age and anti-GAGA4 IgM levels among
the study population. To examine for a relationship
between anti-GAGA4 IgM levels and the risk of an
earlier (i.e. 2 vs. 4 years) second attack, we looked at
patients whose anti-GAGA4 IgM levels were above
the median antibody levels for the FP group as a
whole. Sixteen out of twenty patients (80%) with
antibody titers above median had a second clinical
attack within 2 years compared to only 10/21 (47%)
patients with titers equal or below the median
(odds ratio 4.4 CI 95% 1.1–17.7, Fisher exact test,
P = 0.05).
Cohort-B: Anti-GAGA4 IgM in FP-RRMS versus
OND group
Clinical and demographic characteristics as well as
anti-GAGA4 levels for cohort-B are described in
Table 2. Total IgM levels were significantly higher
in the FP group, and associated with gender and
anti-GAGA4 IgM levels, therefore, we corrected the
total IgM for gender by adding 0.17 (mg/mL)0.5 to
all male samples. Anti-GAGA4 EU were normalized
for total IgM in serum samples by dividing by the
square root of total IgM (mg/mL)0.5 corrected to
gender. There were significant differences between
the OND group versus the FP group in mean age,
gender composition, total IgM corrected for gender,
and anti-GAGA4 IgM. However, more importantly,
the levels of anti-GAGA4 corrected for total IgM was
observed to be significantly higher (P = 0.0001,
Mann–Whitney U-test) in FP patients as opposed
to OND patients. Distribution of normalized anti-
GAGA4 IgM in the FP and OND groups is shown
in Figure 3.
Figure 2 Distribution of anti-GAGA4 IgM levels in cohort-A
[FP (n = 44) and OND (n = 44) patients]. Lines indicate SD
± mean. Crossing line indicates cutoff for defining antibody
status. P-value (Mann–Whitney U) is FP group versus OND.
Table 1 Demographic, clinical characteristics, and anti-GAGA4 IgM levels of cohort-A
FP (n = 44) OND (total n = 44, OIND 21,
ONIND 23)
Ottawa (n = 66) Brussels (n =2 2 )
Mean age, years (SD) 37.6 (9.0) 38.5 (9.5) 39.1 (8.8) 35.1 (9.8)
Female, n (%) 38 (86) 33 (75) 55 (83)a 16 (73)
Center Ottawa, n (%) 37 (84)b 26 (59) NA NA
Total IgM, Mean RFU × 106 (SD) 2.10 (0.80) 1.94 (0.68) 2.08 (0.79) 1.83 (0.53)
2nd relapse within 24 months, n (% of
FP population only)
26 (60)c NA 21 (57) 5 (71)
Anti-GAGA4 IgM, Mean signal intensity,
OD/(Total IgM RFU × 106)0.5 (SD)
0.44 (0.30)d 0.30 (0.11) 0.37 (0.26) 0.35 (0.16)
All FP patients had CDMS at the end of the follow-up.
Other inflammatory neurological disease (OIND) group included the following: 2 bacterial meningitis, 4 viral meningitis, 1 IV Ig-induced
meningitis, 2 optic neuritis, 2 cerebral vasculitis, 1 Churg–Strauss vasculitis, 2 myelitis, 1 sarcoidosis, 1 SLE, 1 HIV, 1 sinusitis, 1 brachial
plexitis, 1 epidural abscess; Other noninflammatory neurological disease (ONIND) group included the following: 2 fibromyalgia,
2 migraine, 5 idiophathic headache, 1 progressive dementia, 1 motor neuron disease, 1 valproate-induced encephalopathy, 1 migraine +
stroke, 1 dementia NYD (not yet determined), 1 neurosis, 1 brainstem stroke, 1 anisocoria, 1 chronic insomnia, 1 diabetic amyotropy,
1 numbness, 1 motor neuropathy, 1 occipital neuralgia and ataxia, 1 breast cancer; NA, not applicable.
Note: All the data in this Table derive from samples collected at or near the time of FP.
FP, first presentation; OND, other neurological diseases; SD, Standard deviation; RFU, relative fluorescence units; OD, optical density.
aχ2 test P = 0.025 versus Brussels.
bχ2 test P = 0.01 versus OND.
cVerified data regarding occurrence of second relapse within 24 months and EDSS score at 4 years were available only for 41 of the
44 FP patients.
dMann–Whitney U-test, P = 0.01 versus OND.
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root total IgM (mg/mL serum), we found that
44/167 (26.3%) FP patients were positive, whereas
77/85 (90.6%) OND patients were negative, corres-
ponding to a sensitivity of 26.3% (95% CI
[19.8–33.7]), a specificity of 90.6% (95% CI
[82.3–95.4]), PPV of 84.6%, and NPV of 38.5%.
Inter-plate CV for calibrator sample was 15%.
Cohort-C: Levels of anti-α glucose IgM in FP
patients that will have a second early relapse
(up to 24 months), versus late or no relapse
Demographics, clinical characteristics, and anti-
glycan antibodies levels of FP (n = 100) patients
who had early relapse (≤24 months, n = 58) versus
late or no relapse (>24 months, n = 42) are described
in Table 3.
Except for time to first relapse, no significant dif-
ferences were found among demographics, clinical
characteristics, and square root total IgM of the
early versus late relapsing group. Therefore, in this
cohort, there was no need to correct for total IgM.
Levels of all anti-glycan antibodies were higher in
the early versus later relapsers, however, this did
not reach statistical significance. To evaluate the
possible relationship between levels of anti-
α-glucose-based glycans IgM levels and the risk of
imminent (i.e. within 24 months) first relapse, we
looked at positive patients whose antibodies levels
were above cutoff levels for at least one of the four
antibodies versus patients negative for all four anti-
bodies. Twenty-two (22/58 (38%) early relapsing
patients were positive for at least one antibody com-
pared to only 5/42 (12%) positive patients that had
a late or no relapse at all, (P = 0.003 χ2 test, odds
ratio = 4.5 (95% CI [1.5–13.2]), 0.0125 (Bonferroni
correction) should be considered the significant
threshold for this analysis since four different
methods for determining the cutoff values of the
Table 2 Demographic, clinical characteristics and anti-GAGA4 IgM levels of cohort-B
FP (n = 167) OND (n = 85) OIND,
n =3 3 ,O N I N D ,n =5 2
Ottawa
(n = 177)
Brussels (n =7 5 )
Mean age, years (SD) 37 (10)a 44 (10) 39 (11) 39 (10)
Female, n (%) 126 (75)a 44 (52) 128 (72)b 42 (56)
Center Ottawa, n (%) 121 (72) 56 (66) NA NA
Total IgM(mg/mL)0.5, corrected for gender,
mean (SD)
1.32 (0.27)c 1.21 (0.28) 1.29 (0.28) 1.25 (0.26)
Anti-GAGA4 IgM, Units, mean (SD) 47.7 (27.1)c 36.7 (33.5) 46.3 (32.3)b 38.6 (22.2)
Anti-GAGA4 IgM, Units/Total IgM (mg/mL)0.5,
corrected for gender, mean (SD)
36.4 (23.1)c 29.9 (23.2) 35.5 (25.8) 31.2 (15.4)
Other inflammatory neurological disease (OIND) group included the following: 1 bacterial meningitis, 1 Aspergillus meningitis, 5 viral
meningitis, 4 optic neuritis, 1 cerebral vasculitis, 1 vasculitic neuropathy, 1 cerebral malaria, 2 myelitis, 1 neurosarcoidosis, 1 chronic
meningitis, 1 neurosyphilis, 3 HIV encephalopathy, 1 Sjögren encephalopathy, 1 Grave’s disease, 4 Guilain-Barre syndrome, 1 chronic
inflammatory demyelinating polyneuropathy, 1 acute disseminated encephalomyelitis, 1 Brachial plexopathy, 1 carcinomatous men-
ingitis, 1 infectious meningitis of unknown origin; Other non-inflammatory neurological disease (ONIND) group included the follow-
ing: 1 adrenomyelopathy, 1 amyotrophic lateral sclerosis, 2 anxiety, 3 idiopathic intracranial hypertension, 2 cerebrovascular disease,
1 cervical cancer, 2 neurodegenerative dementia, 2 degenerative disc disease, 2 diabetic retinopathy, 1 dizziness, 1 facial myokimia,
2 fibromyalgia, 1 glioblastoma multiforme, 8 idiopathic headache, 1 nerve palsy, 1 intermittent diplopia, 2 labyrinthitis, 1 left sixth
nerve palsy, 1 lymphoma of cavum, 1 meningismus, 1 motor neuron disease, 1 motor neuropathy, 1 myelopathy, 1 neuralgia,
1 neurogenic bladder, 1 nystagmus, 1 optic neuropathy left eye, 2 papilledema, 1 pituitary tumor, 1 psychiatric disorder, 1 quadri-
plegia, 1 tingling NYD, 1 vertical diplopia/mild ptosis, 2 vertigo; NA, not applicable.
aP < 0.05 versus OND.
bP < 0.05 versus Brussels.
cMann–Whitney U-test Total IgM FP vs. OND P = 0.004; Anti-GAGA4 IgM FP vs. OND P < 0.0001; Anti-GAGA4 IgM corrected for
gender FP vs.OND P = 0.0001.
Figure 3 Distribution of anti-GAGA4 IgM levels in cohort-B
[FP patients (n = 167), and OND (n = 85)]. Lines indicate SD
± mean. Crossing line indicates cutoff value for antibody sta-
tus. P-value (Mann-Whitney U) is FP group versus OND.
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did not experience a second attack within the study
period, only one was antibody-positive. Kaplan–
Meier survival plot comparison (Figure 4) between
cumulative risk of FP patients who were positive
for at least one marker (anti-GAGA4, -GAGA2,
-GAGA3, or -GAGA6 IgM) versus negative patients
revealed significant differences between the groups
(P = 0.0025 for up to 24 months, respectively) indi-
cating that antibody positive patients consistently
had their first relapse earlier. A high level in at least
one of the anti-α-glucose IgM antibodies, identified
37.9% of FP patients who had an early attack
(<24 months) versus those who had a late or no
attack within the follow-up period with 88.1% speci-
ficity, 81.5% PPV, and 50.7% NPV (Table 4).
Discussion
A diagnostic or prognostic biomarker involving a
simple serological test would represent a significant
advance in the management of relapsing MS. There
are numerous candidate serum antibodies that are
purported to be useful as MS biomarkers. Of these, it
is notable that a number of anti-glycan antibodies
have been considered [2,3,10]. As a result of system-
aticscreening usingtheGlycoChip®glycanarray,we
previously found significantly elevated levels of anti-
GAGA4 IgM antibodies in MS patients compared to
OND patients. These levels differentiated MS from
OND with 57% sensitivity and 85% specificity [6].
Table 3 Demographic characteristics, clinical characteristics,
and anti-glycan antibodies levels of FP (n = 100) patients who
had early relapse (≤24 months) versus late or no relapse
(>24 months) in cohort-C
Early relapse,
≤24 m (n =5 8 )
Late or no relapse,
>24 m (n =4 2 ) a
Mean age, years (SD) 34.9 (10.9) 36.2 (8.2)
Female, n (%) 43 (74) 29 ( 69)
Center Ottawa, n (%) 22 (38) 23 (54)
Square root total IgM,
Mean mg/mL (SD)
1.18 (0.26) 1.13 (0.20)
Time to relapse, Mean
months (SD)b
11.4 (7.0) 44.8 (18.8)c
Anti-GAGA2 IgM levels,
Mean (SD)
2.4 (1.3) 2.2 (0.9)
Anti-GAGA3 IgM levels,
Mean (SD)
2.5 (1.3) 2.2 (0.9)
Anti-GAGA4 IgM levels,
Mean (SD)
2.4 (1.3) 2.0 (1.1)
Anti-GAGA6 IgM levels,
Mean (SD)d
3.1 (1.9) 2.4 (1.1)
SD, Standard deviation.
a11 patients remain still FP without drug treatment, 2 patients
for 72 months and 9 patients for 48 months.
bCalculated only for patients who had relapse during the follow-
up time.
cP < 0.0001, T-test.
dFisher exact test of anti-GAGA6 status (positive or negative) vs.
early/late relapse, P = 0.015, Odds Ratio 6.4 (95%CI 1.4–29.8).
Figure 4 Time to CDMS, Kaplan–Meier, survival plot for
cohort-C. FP patients positive for ≥1 (anti-GAGA4, -GAGA2,
-GAGA3, or -GAGA6 IgM) versus patients negative for all
markers. Cutoff values were 4.0, 4.5, 4.5, and 4.3 for anti-
GAGA2, -GAGA3, -GAGA4, and -GAGA6 IgM, respectively.
P-values determined by log rank test. With Bonferroni correc-
tion only P-values below 0.0125 are considered significant.
Table 4 Diagnostic characteristics for identification of FP patients who had an early relapse (≤24 months, n = 58) vs. late or no
relapse (>24 months, n = 42) using a panel of anti-α-glucose disaccharide and different cutoffs (Cohort C)
Cutoff useda Mean + SD Mean + 1.5 SD Mean + 2 SD Best fit
Sensitivity, % (95% CI) 37.9 (25.5–51.6) 24.1 (13.9–37.2) 15.5 (7.3–27.4) 37.9 (25.5–51.6)
Specificity, % (95% CI) 83.3 (68.6–93.0) 88.1 (74.4–96.0) 95.2 (83.8–99.4) 88.1 (74.4–96.0)
PPV, % 75.9 73.7 81.8 81.5
NPV, % 49.3 45.7 44.9 50.7
Efficiency, % 57.0 51.0 49.0 59.0
Relative riskb 1.5 2.5 3.3 3.2
SD, Standard deviation, CI, confidence intervals; PPV, positive predictive value; NPV, negative predictive value.
aCutoffs were calculated for each marker using mean of all 100 FP samples plus 1, 1.5, and 2 SD; PPV; and NPV.
bRelative risk of patient positive for at least one marker among the four markers for having second relapse in up to 24 months versus
negative patients.
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examining how early in the course of disease the
antibodies can be found and determining whether
their titers are predictive of disease activity.
Testing a total of 311 frozen sera samples taken
from FP patients at or near the time of their first
neurological event, and 129 samples from OND
patients, we showed that MS patients express
higher levels of anti-GAGA4 IgM antibodies, indi-
cating that anti-glycan reactivity probably occurs
very early in the disease course. More importantly,
we were able to demonstrate that FP patients with
higher levels of a panel of anti-α-glucose IgM anti-
bodies had a higher probability for having a sec-
ond attack within 24 months. In fact, patients
who are positive for at least one of the anti-
α-glucose IgM antibodies had significantly higher
cumulative risk (Kaplan–Meier) for having an ear-
lier relapse, identifying about a third of all the
early relapsers. An interesting categorical analysis
revealed that anti-GAGA6 status alone (positive or
negative) had the strongest predictive value of an
early relapse.
In the initial discovery phase [6] we screened 40
different glycans and found that IgM (not IgG or
IgA) antibodies to α-glucose antigens could distin-
guish MS patients from OND controls. This type
of IgM response to carbohydrates is most likely
produced by self-replenishing B-1 B cells, which
respond poorly to protein, but much better to
carbohydrate antigens [11]. In general, B1 B-cells
require a high amount of antigen for induction
and play an important role as a first line of defense
against invading pathogens, removal of senescent
cells, cell debris, and other self-antigens [12,13].
Interestingly, serum-derived human IgM monoclo-
nal antibodies were found to accumulate in areas of
CNS damage and promote remyelination in demye-
linated mice [14,15]. This possibly reflects a type of
“house-keeping” role, a recognized property of these
antibodies [12]. Also, in agreement with the present
study, higher levels of IgM antibodies in CSF were
found to predict a more severe MS course [16]. It
would, therefore, be worthwhile to also test for the
presence of anti-α-glucose IgM antibodies in the
CSF of MS patients; although, a simple blood test
would still be more preferable, especially if it
needed to be repeated.
The biological basis of a humoral response to
α-glucose antigen is still unclear, but it is of interest
that this particular carbohydrate (α-glucose) is
found within the type IV collagen matrix of the
blood–brain barrier (BBB) [17]. A common struc-
tural feature of type IV collagen is hydroxyl-
lysine-linked disaccharides that are comprised of
α-glucose and β-galactose subunits (Glc(α1,2)Gal(β))
[18]. This disaccharide was previously reported to
be the most important immunogenic antigen of
patients having anti-glomerular basement mem-
brane antibody–mediated glomerulonephritis [19].
As immune cells traverse the BBB, facilitated by the
release of metalloproteases that help to further
breakdown the BBB extracellular matrix, the ongo-
ing inflammatory response can lead to the release
of this carbohydrate antigen, thus stimulating an
immune reaction. The subsequent development of
IgM antibodies could then also contribute to further
damage to the BBB by attacking the antigen in situ.
Interestingly, type IV collagen deposits can also be
found within MS plaques [20]. Also, similar to the
present study, an IgM antibody response to glycans
released from degrading collagen was reported for
rheumatoid arthritis [21], where authors claimed
that the natural IgM antibodies were produced
against the glycosaminoglycans, including glucose
molecules, which were degraded and released from
the cartilage matrix. In addition, α-glucose–based
polysaccharides are found in the cell wall of several
pathogenic fungi [22] and bacteria [23,24]. This
homology between known pathogens and a human
α-glucose glycan may suggest that IgM antibodies
could arise through the mechanism of molecular
mimicry, triggering a cross-reactive response that
targets the same glycan in the BBB [25].
As this was a retrospective study, we did not
uniformly perform timely MRI studies as is the
case today for making a definitive diagnosis based
on the new McDonald criteria [26,27]. It might
have been of interest to compare early MRI para-
meters predictive of disease to antibody levels to
formulate an overall prediction of an early first
r e l a p s e( i . e .C D M S ) .A n a l y s i so ft h eE a r l yT r e a t -
ment of MS (ETOMS) study population (308 FP
patients and an abnormal MRI) showed that out
of the 121 patients who converted toCDMSwithin
2 years of follow-up, 112 (93%) had ≥3m o d i f i e d
Barkhof MRI criteria [28]. However, 155 out of the
187 patients (83%) who didn’tc o n v e r tt oC D M S
within 24 months also had ≥3 modified Barkhof
MRI criteria [26–30], yielding a 93% sensitivity, but
only 17% specificity, PPV 42%, and NPV 78% for
MRI predicting early CDMS conversion. MRI seems
more sensitive at predicting ultimate vs. imminent
conversion to CDMS. Although this cannot be
directly compared to the diagnostic performance
of antibody measurement in our retrospective
study of FP patients (37% sensitivity, 88% speci-
ficity, 81% PPV, and 50% NPV), it suggests
that measuring anti-α-glucose IgM levels could
provide an independent and more specific predic-
tive factor for early conversion to CDMS (within
24 months). Finding higher levels of serum anti-
GAGA2, -GAGA3, -GAGA4, or -GAGA6 IgM anti-
bodies in FP patients seems to predict, with high
specificity, those who will convert to CDMS within
2 years. Such information might be invaluable for
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a course of early therapy for their FP patients. Defin-
itive conclusions can only be drawn, however, from
a prospective study on additional cohorts that mea-
sures anti-glycan antibodies together with MRI and
clinical outcomes.
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